GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data ...

Columnist Sam Kirton finds that filling the silence is part of living with a chronic condition, especially amid retirement and COVID-19.

Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic ...

Columnist Sam Kirton describes how daunting an IPF prognosis can be — but also how things are looking up for patients today.

Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.

IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

A Phase 3 clinical trial testing Boehringer Ingelheim ’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

The U.S. Food and Drug Administration has granted Bristol Myers Squibb’s investigational therapy BMS-986278 breakthrough therapy status.

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...